What is aducanumab?
Aducanumab is the Newest clinical treatment for Dementia and Alzheimer’s disease. Currently, The Drug-maker Biogen Agency Reviewed Aducanumab for Alzheimer’s In June 2022 and They Approved The Aducanumab (Aduhelm) as a New Treatment for Alzheimer’s Disease, But Since December 2021 A European Research Agency Refused this Drug to Use for Alzheimer’s Disease.
Who can take aducanumab?
Aducanumab Treatment not suitable for all Patients at all stages of dementia. and U.S. FDA Drug Research Recommends That, The Aducanumab Should only can used for People living with early stages of Alzheimer’s disease. or mild cognitive impairment (MCI).
How is aducanumab intended to work?
Aducanumab has been reported to slow the decline of cognitive skills and functional capacity. It clears the brain of amyloid beta, which is thought to cause Alzheimer’s disease.
However, these effects have only been shown in people living with mild memory or thinking problems.
Aducanumab is administered as an intravenous (IV) infusion every four weeks. Patients receiving aducanumab treatment should undergo brain magnetic resonance imaging (MRI) multiple times before and after treatment.
Side effects of aducanumab may include amyloid-related imaging abnormalities (ARIA) (brain swelling and microhemorrhage), superficial siderosis (toxic deposition of protein), skin swelling, hives, headache, confusion, delirium, altered mental status, confusion, collapse, dizziness. , vertigo, visual disturbances, nausea and diarrhea.
Another reason to be cost conscious. When it first appeared on the US market in June 2021, aducanumab cost about $4,312 USD per infusion, or about $56,000 USD annually.
On December 20, 2021, the drug maker, Biogen, announced that it would lower the price of the drug. As of January 1, 2022, the annual cost of the drug will be Around $28,200 USD. The exact cost varies depending on the patient’s weight and their dosage.
What medications are available to treat Alzheimer’s disease?
Currently There’re 4 Medications Available to Treat Symptoms of Alzheimer’s Disease, which approved By Canadian Ministry of Health, and These Medications can slow the cognitive decline Rate, and Help to improve thinking abilities and movement.
There are several drugs currently being tested through clinical trials. In total, in 2020, there were 126 agents in 152 trials assessing new therapies for Alzheimer’s disease:
- 28 treatments in Phase 3 trials,
- 74 in Phase 2, and
- 24 in Phase 1.
Alzheimer’s disease and other dementias are complex and not yet fully understood, Presently Many Research Focuses on This Study for Finding more accurate Treatment information,
Some promising targets for new treatments to slow or stop the Progress of the disease have been identified by researchers (such as, neuroinflammation, and buildup of beta-amyloid and tau in thehuman brain).
It’s believed that future treatments will involve risk reduction strategies and the combination of targeted medications or devices that address several disease targets.
While the number of potential treatment options currently being explored represents a significant improvement over the years,
dementia research funding is still far behind any other major disease resulting in fewer drugs in the pipeline of clinical trials.
Actually There’re more research needed to explore better treatments options for all people living with dementia.
Also Read: What are Protein?